Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

4D Pharma plc (DDDD) Ordinary 0.25p

Sell:66.10p Buy:66.70p 0 Change: 0.90p (1.34%)
Market closed Prices as at close on 24 September 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:66.10p
Buy:66.70p
Change: 0.90p (1.34%)
Market closed Prices as at close on 24 September 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:66.10p
Buy:66.70p
Change: 0.90p (1.34%)
Market closed Prices as at close on 24 September 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

4D pharma plc (4D), formerly Schosween 18 Limited, is a United Kingdom-based pharmaceutical company focusing on developing various projects targeting new therapeutic areas. The principal activity of the Company is research and development of pharmaceutical products in new live biotherapeutic areas. The Company has developed its research to build MicroRx, which is a discovery methodology that is able to rationally select those bacteria that have a precise and evolved therapeutic effect. Its MicroRx methodology offers a pipeline of approximately 10 therapeutic programs covering autoimmune diseases, central nervous system (CNS) disorders and cancer. The Company uses MicroRx to develop its programs into the clinic and has approximately two programs in patient trials. The Company focuses on immune conditions, such as pediatric Crohn's, pediatric colitis and irritable bowel syndrome.

Contact details

Address:
9 Bond Court
LEEDS
LS1 2JZ
United Kingdom
Telephone:
+44 (0113) 8950130
Website:
https://www.4dpharmaplc.com/

Important dates

Future events
There are no future events available.
Past events
AGM 24 May 2021 24/05/21
Annual report 15 April 2021 15/04/21
Final results 01 April 2021 01/04/21
General meeting 18 March 2021 18/03/21
Interim results 30 September 2020 30/09/20

General stock information

EPIC:
DDDD
ISIN:
GB00BJL5BR07
Market cap:
£119.90 million
Shares in issue:
180.30 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Duncan Peyton
    Chief Executive Officer, Executive Director
  • Alexander Stevenson
    Chief Scientific Officer, Executive Director
  • Glenn Dourado
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.